Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Sarcoma, Soft-tissue
Interventions
DRUG

pazopanib

Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break

Trial Locations (4)

65929

Klinikum Frankfurt-Höchst, Frankfurt am Main

68135

University Hospital Mannheim, Dpt. of Surgery, Mannheim

69120

German Cancer Research Center, Medical PET Group - Biological Imaging, Heidelberg

University Hospital Heidelberg / National Centre for Tumor Diseases, Heidelberg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Universitätsmedizin Mannheim

OTHER

collaborator

Klinikum Frankfurt Höchst

OTHER

collaborator

German Cancer Research Center

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

University Hospital Heidelberg

OTHER

lead

Heidelberg University

OTHER

NCT01543802 - Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter